{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:22:57Z","timestamp":1778800977676,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019\u2013106666RB-I00"],"award-info":[{"award-number":["PID2019\u2013106666RB-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011941","name":"Gobierno del Principado de Asturias","doi-asserted-by":"publisher","award":["BP-21\u2013084"],"award-info":[{"award-number":["BP-21\u2013084"]}],"id":[{"id":"10.13039\/100011941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011941","name":"Gobierno del Principado de Asturias","doi-asserted-by":"publisher","award":["BP\u2010 20\u2013046"],"award-info":[{"award-number":["BP\u2010 20\u2013046"]}],"id":[{"id":"10.13039\/100011941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011941","name":"Gobierno del Principado de Asturias","doi-asserted-by":"publisher","award":["IDI\/2021\/000027"],"award-info":[{"award-number":["IDI\/2021\/000027"]}],"id":[{"id":"10.13039\/100011941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.biopha.2023.114627","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T17:12:33Z","timestamp":1680541953000},"page":"114627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling"],"prefix":"10.1016","volume":"162","author":[{"given":"\u00d3scar","family":"Estupi\u00f1\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Torn\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dzohara","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borja","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Huergo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Blanco-Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Victoria Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Moris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Ayll\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Ramos-Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bigas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biopha.2023.114627_bib1","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911131","article-title":"Sarcoma treatment in the era of molecular medicine","volume":"12","author":"Grunewald","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2023.114627_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/07357907.2020.1768401","article-title":"Epidemiology and risk factors of osteosarcoma","volume":"38","author":"Sadykova","year":"2020","journal-title":"Cancer Investig."},{"issue":"Suppl 4","key":"10.1016\/j.biopha.2023.114627_bib3","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","article-title":"Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.114627_bib4","doi-asserted-by":"crossref","first-page":"3631764","DOI":"10.1155\/2016\/3631764","article-title":"Osteosarcoma: cells-of-origin, cancer stem cells, and targeted therapies","volume":"2016","author":"Abarrategi","year":"2016","journal-title":"Stem Cells Int."},{"issue":"12","key":"10.1016\/j.biopha.2023.114627_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10122621","article-title":"Cancer stem cells as a source of drug resistance in bone sarcomas","volume":"10","author":"Men\u00e9ndez","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2023.114627_bib6","series-title":"Bone Sarcomas and Bone Metastases - From Bench to Bedside","first-page":"371","article-title":"Chapter 28 - Cancer stem cells and clonal evolution in bone sarcomas","author":"Rodr\u00edguez","year":"2022"},{"issue":"1","key":"10.1016\/j.biopha.2023.114627_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2015.07.048","article-title":"Notch signaling: an emerging therapeutic target for cancer treatment","volume":"369","author":"Yuan","year":"2015","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.biopha.2023.114627_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ccr.2014.07.023","article-title":"Notch activation as a driver of osteogenic sarcoma","volume":"26","author":"Tao","year":"2014","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.biopha.2023.114627_bib9","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.18632\/aging.202314","article-title":"Notch-1 promotes the malignant progression of osteosarcoma through the activation of cell division cycle 20","volume":"13","author":"Gao","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.biopha.2023.114627_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-319-04843-7_4","article-title":"Understanding the role of Notch in osteosarcoma","volume":"804","author":"McManus","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2023.114627_bib11","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1541-7786.MCR-19-0493","article-title":"The Notch Pathway Promotes Osteosarcoma Progression through Activation of Ephrin Reverse Signaling","volume":"17","author":"Yu","year":"2019","journal-title":"Mol. Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2023.114627_bib12","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3892\/ol.2017.5708","article-title":"Notch signaling is important for epithelial-mesenchymal transition induced by low concentrations of doxorubicin in osteosarcoma cell lines","volume":"13","author":"Yang","year":"2017","journal-title":"Oncol. Lett."},{"issue":"22","key":"10.1016\/j.biopha.2023.114627_bib13","doi-asserted-by":"crossref","first-page":"33055","DOI":"10.18632\/oncotarget.8849","article-title":"Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114627_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pharmthera.2015.05.008","article-title":"J. Portugal, Sp1 transcription factor: a long-standing target in cancer chemotherapy","volume":"152","author":"Vizca\u00edno","year":"2015","journal-title":"Pharm. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2023.114627_bib15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00000441-198711000-00015","article-title":"Mithramycin selectively inhibits transcription of G-C containing DNA","volume":"294","author":"Miller","year":"1987","journal-title":"Am. J. Med Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.114627_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13046-017-0617-y","article-title":"Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation","volume":"36","author":"Dong","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.114627_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12951-021-01008-x","article-title":"Mithramycin delivery systems to develop effective therapies in sarcomas","volume":"19","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"7","key":"10.1016\/j.biopha.2023.114627_bib18","first-page":"1358","volume":"10","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Nano-Encapsulation Mithramycin Transf. Polym. Micelles Treat. Sarcomas"},{"issue":"1","key":"10.1016\/j.biopha.2023.114627_bib19","doi-asserted-by":"crossref","first-page":"15202","DOI":"10.1038\/s41598-019-50917-3","article-title":"Mithramycin a inhibits colorectal cancer growth by targeting cancer stem cells","volume":"9","author":"Quarni","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2023.114627_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.trsl.2014.10.011","article-title":"Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin","volume":"165","author":"Saha","year":"2015","journal-title":"Transl. Res."},{"issue":"4","key":"10.1016\/j.biopha.2023.114627_bib21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.celrep.2016.12.064","article-title":"Oncogenes activate an autonomous transcriptional regulatory circuit that drives glioblastoma","volume":"18","author":"Singh","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.114627_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccr.2014.05.005","article-title":"Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma","volume":"26","author":"Vanner","year":"2014","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.biopha.2023.114627_bib23","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1055\/s-0035-1557876","article-title":"Expanding the chemical diversity of the antitumoral compound mithramycin by combinatorial biosynthesis and biocatalysis: the quest for mithralogs with improved therapeutic window","volume":"81","author":"M\u00e9ndez","year":"2015","journal-title":"Planta Med."},{"issue":"12","key":"10.1016\/j.biopha.2023.114627_bib24","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1021\/jm300234t","article-title":"A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis","volume":"55","author":"N\u00fa\u00f1ez","year":"2012","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2023.114627_bib25","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1021\/jm300234t","article-title":"A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis","volume":"55","author":"N\u00fa\u00f1ez","year":"2012","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.biopha.2023.114627_bib26","first-page":"4105","article-title":"Identification of mithramycin analogues with improved targeting of the EWS-FLI1 transcription factor. clinical cancer research: an official journal of the American Association for","volume":"22","author":"Osgood","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.114627_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.omto.2020.06.001","article-title":"Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma","volume":"18","author":"Federico","year":"2020","journal-title":"Mol. Ther. - Oncolytics"},{"issue":"8","key":"10.1016\/j.biopha.2023.114627_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104687","article-title":"J. Portugal, Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue","volume":"9","author":"Vizca\u00edno","year":"2014","journal-title":"PLoS One"},{"issue":"32","key":"10.1016\/j.biopha.2023.114627_bib29","doi-asserted-by":"crossref","first-page":"32856","DOI":"10.18632\/oncotarget.5942","article-title":"Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2","volume":"6","author":"Pandiella","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.biopha.2023.114627_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040964","article-title":"SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications","volume":"12","author":"Menendez","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.biopha.2023.114627_bib31","doi-asserted-by":"crossref","first-page":"30935","DOI":"10.18632\/oncotarget.8817","article-title":"Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma","volume":"7","author":"Tornin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114627_bib32","first-page":"1157","article-title":"The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042","author":"Hermida-Prado","year":"2019","journal-title":"8 (8)"},{"issue":"4","key":"10.1016\/j.biopha.2023.114627_bib33","first-page":"415","article-title":"Transcriptional reprogramming and inhibition of tumor-propagating stem-like cells by EC-8042 in ERG-positive Prostate Cancer. European Urology","volume":"2","author":"Shinde","year":"2019","journal-title":"Oncology"},{"issue":"16","key":"10.1016\/j.biopha.2023.114627_bib34","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00018-015-1918-y","article-title":"Bone microenvironment signals in osteosarcoma development","volume":"72","author":"Alfranca","year":"2015","journal-title":"Cell Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.biopha.2023.114627_bib35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.stemcr.2014.08.005","article-title":"Human bone marrow stromal cells lose immunosuppressive and anti-inflammatory properties upon oncogenic transformation","volume":"3","author":"Rodriguez","year":"2014","journal-title":"Stem Cell Rep."},{"issue":"10","key":"10.1016\/j.biopha.2023.114627_bib36","first-page":"2061","volume":"31","author":"Rodriguez","year":"2013","journal-title":"Expr. FUS-CHOP Fusion Protein Immortal. \/Transform. Hum. mesenchymal stem Cells Drives mixoid liposarcoma Form."},{"issue":"1","key":"10.1016\/j.biopha.2023.114627_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ijc.32081","article-title":"The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas","volume":"145","author":"Estupi\u00f1an","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2023.114627_bib38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neo.2017.03.004","article-title":"Trabectedin and campthotecin synergistically eliminate cancer stem cells in cell-of-origin sarcoma models","volume":"19","author":"Martinez-Cruzado","year":"2017","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.biopha.2023.114627_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126425","article-title":"Addressing doxorubicin resistance in bone sarcomas using novel drug-resistant models","volume":"23","author":"Gallego","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.114627_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.231","article-title":"DNA replication stress in CHK1-depleted tumour cells triggers premature (S-phase) mitosis through inappropriate activation of Aurora kinase B","volume":"5","author":"Zuazua-Villar","year":"2014","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.114627_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neo.2017.11.004","article-title":"FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC\/FAK\/RHO\/ROCK-dependent pathway","volume":"20","author":"Tornin","year":"2018","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.biopha.2023.114627_bib42","doi-asserted-by":"crossref","first-page":"27878","DOI":"10.1038\/srep27878","article-title":"Aldh1 expression and activity increase during tumor evolution in sarcoma cancer stem cell populations","volume":"6","author":"Martinez-Cruzado","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.114627_bib43","series-title":"Sarcoma Stem Cell Heterogeneity, in Stem Cells Heterogeneity - Novel Concepts","first-page":"95","author":"Hatina","year":"2019"},{"key":"10.1016\/j.biopha.2023.114627_bib44","series-title":"The Role Played by Cancer Stem Cells, in Stem Cells Heterogeneity in Cancer","first-page":"187","article-title":"The Heterogeneity of Osteosarcoma","author":"Schiavone","year":"2019"},{"key":"10.1016\/j.biopha.2023.114627_bib45","first-page":"70","article-title":"Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer","volume":"9","author":"Schweer","year":"2021"},{"issue":"11","key":"10.1016\/j.biopha.2023.114627_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140786","article-title":"Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-\u00df-D-Digitoxosyl-Mithramycin SK (EC-8042)","volume":"10","author":"Fern\u00e1ndez-Guiz\u00e1n","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2023.114627_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cbi.2014.05.019","article-title":"J. Portugal, The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription","volume":"219","author":"Fern\u00e1ndez-Guiz\u00e1n","year":"2014","journal-title":"Chem. Biol. Inter."},{"issue":"4","key":"10.1016\/j.biopha.2023.114627_bib48","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2018.07.009","article-title":"Notch signaling in the tumor microenvironment","volume":"34","author":"Meurette","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.biopha.2023.114627_bib49","first-page":"29","article-title":"Analysis of changes in the expression of Notch1 and HES1 and the prognosis of osteosarcoma patients following surgery","volume":"20","author":"Fang","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2023.114627_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/sci.2018.02.02","article-title":"Targeting Notch signalling pathway of cancer stem cells","volume":"5","author":"Venkatesh","year":"2018","journal-title":"Stem Cell Invest."},{"issue":"8","key":"10.1016\/j.biopha.2023.114627_bib51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","article-title":"Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update","volume":"12","author":"Takebe","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114627_bib52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2016.194","article-title":"MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1","volume":"36","author":"Lu","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2023.114627_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mc.22873","article-title":"Notch pathway inhibition using DAPT, a \u03b3-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma","volume":"58","author":"Dai","year":"2019","journal-title":"Mol. Carcinog."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223004158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223004158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:31:39Z","timestamp":1778247099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223004158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":53,"alternative-id":["S0753332223004158"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114627","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114627"}}